These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21624090)

  • 21. Composition and topology of activity cliff clusters formed by bioactive compounds.
    Stumpfe D; Dimova D; Bajorath J
    J Chem Inf Model; 2014 Feb; 54(2):451-61. PubMed ID: 24437577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioactivity landscape modeling: chemoinformatic characterization of structure-activity relationships of compounds tested across multiple targets.
    Waddell J; Medina-Franco JL
    Bioorg Med Chem; 2012 Sep; 20(18):5443-52. PubMed ID: 22178187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity cliffs: facts or artifacts?
    Medina-Franco JL
    Chem Biol Drug Des; 2013 May; 81(5):553-6. PubMed ID: 23375049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity cliff networks for medicinal chemistry.
    Stumpfe D; Bajorath J
    Drug Dev Res; 2014 Aug; 75(5):291-8. PubMed ID: 25160069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extending the activity cliff concept: structural categorization of activity cliffs and systematic identification of different types of cliffs in the ChEMBL database.
    Hu Y; Bajorath J
    J Chem Inf Model; 2012 Jul; 52(7):1806-11. PubMed ID: 22758389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic Assessment of Molecular Selectivity at the Level of Targets, Bioactive Compounds, and Structural Analogues.
    Hu Y; Bajorath J
    ChemMedChem; 2016 Jun; 11(12):1362-70. PubMed ID: 26358784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards a systematic characterization of the antiprotozoal activity landscape of benzimidazole derivatives.
    Pérez-Villanueva J; Santos R; Hernández-Campos A; Giulianotti MA; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2010 Nov; 18(21):7380-91. PubMed ID: 20888242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single R-Group Polymorphisms (SRPs) and R-cliffs: an intuitive framework for analyzing and visualizing activity cliffs in a single analog series.
    Agrafiotis DK; Wiener JJ; Skalkin A; Kolpak J
    J Chem Inf Model; 2011 May; 51(5):1122-31. PubMed ID: 21504183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring global growth of activity cliff information over time and assessing activity cliff frequencies and distributions.
    Stumpfe D; Bajorath J
    Future Med Chem; 2015 Aug; 7(12):1565-79. PubMed ID: 26334207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extraction of SAR information from activity cliff clusters via matching molecular series.
    Dimova D; Bajorath J
    Eur J Med Chem; 2014 Nov; 87():454-60. PubMed ID: 25282268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introducing a new category of activity cliffs with chemical modifications at multiple sites and rationalizing contributions of individual substitutions.
    Stumpfe D; Hu H; Bajorath J
    Bioorg Med Chem; 2019 Aug; 27(16):3605-3612. PubMed ID: 31272836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
    Dimova D; Hu Y; Bajorath J
    J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computational analysis of activity and selectivity cliffs.
    Peltason L; Bajorath J
    Methods Mol Biol; 2011; 672():119-32. PubMed ID: 20838966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity cliffs in PubChem confirmatory bioassays taking inactive compounds into account.
    Hu Y; Maggiora GM; Bajorath J
    J Comput Aided Mol Des; 2013 Feb; 27(2):115-24. PubMed ID: 23296990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARANEA: a freely available program to mine structure-activity and structure-selectivity relationship information in compound data sets.
    Lounkine E; Wawer M; Wassermann AM; Bajorath J
    J Chem Inf Model; 2010 Jan; 50(1):68-78. PubMed ID: 20053000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analogues.
    Furtmann N; Hu Y; Bajorath J
    J Med Chem; 2015 Jan; 58(1):252-64. PubMed ID: 25054653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic extraction of structure-activity relationship information from biological screening data.
    Wawer M; Bajorath J
    ChemMedChem; 2009 Sep; 4(9):1431-8. PubMed ID: 19621333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large-scale assessment of activity landscape feature probabilities of bioactive compounds.
    Kayastha S; Dimova D; Iyer P; Vogt M; Bajorath J
    J Chem Inf Model; 2014 Feb; 54(2):442-50. PubMed ID: 24410456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conditional probabilities of activity landscape features for individual compounds.
    Vogt M; Iyer P; Maggiora GM; Bajorath J
    J Chem Inf Model; 2013 Jul; 53(7):1602-12. PubMed ID: 23789585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families.
    Hu Y; Wassermann AM; Lounkine E; Bajorath J
    J Med Chem; 2010 Jan; 53(2):752-8. PubMed ID: 20000355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.